Literature DB >> 30324547

Obstructive sleep apnea and self-reported functional impairment in revascularized patients with coronary artery disease in the RICCADSA trial.

Lynn M Baniak1, Eileen R Chasens2, Faith S Luyster2, Patrick J Strollo3,4, Erik Thunström5,6, Yüksel Peker3,5,7,8.   

Abstract

PURPOSE: Daytime sleepiness, a frequent symptom of obstructive sleep apnea (OSA), can impact functional status. In patients with coronary artery disease (CAD) and concomitant OSA, the distinction between sleep-related functional impairment from underlying CAD versus OSA is unclear. This study evaluated the impact of OSA on sleep-related functional impairment in patients with CAD and compared the effect of 1-year continuous positive airway pressure (CPAP) use on change in impairment between those with and without excessive daytime sleepiness (EDS) and OSA. We hypothesized that sleep-related functional impairment is impacted by EDS independent of OSA in patients with CAD.
METHODS: One hundred five CAD patients without OSA and 105 with moderate-to-severe OSA from the RICCADSA trial were matched on disease severity and included in the current substudy. Of those with OSA, 80 were allocated to CPAP. Functional Outcomes of Sleep Questionnaire (FOSQ) score < 17.9 corresponded to sleep-related functional impairment.
RESULTS: Following revascularization, CAD patients with and without OSA frequently report sleep-related functional impairment (35% and 27.3%, respectively; p = .29). Moderate-to-severe OSA was not related to baseline FOSQ scores < 17.9 in regression analyses; EDS was (OR 4.82, 95% CI 2.12-11.0; p < .001). CPAP use significantly improved FOSQ scores from baseline to 1-year follow-up in OSA patients with EDS (17.2 ± 2.0 to 18.15 ± 1.7, p = .002) despite suboptimal adherence.
CONCLUSIONS: Sleep-related functional impairment may be reflective of persistent EDS, independent of OSA. Diagnosing OSA and initiating treatment are worthwhile in individuals with CAD and EDS, as both are important to guide appropriate therapy in patients with CAD.

Entities:  

Keywords:  Continuous positive airway pressure; Coronary artery disease; Functional status; Obstructive sleep apnea

Mesh:

Year:  2018        PMID: 30324547      PMCID: PMC6391726          DOI: 10.1007/s11325-018-1733-4

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  29 in total

1.  Polysomnography indexes are discordant with quality of life, symptoms, and reaction times in sleep apnea patients.

Authors:  Edward M Weaver; B Tucker Woodson; David L Steward
Journal:  Otolaryngol Head Neck Surg       Date:  2005-02       Impact factor: 3.497

2.  Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort.

Authors:  Harneet K Walia; Nicolas R Thompson; Irene Katzan; Nancy Foldvary-Schaefer; Douglas E Moul; Reena Mehra
Journal:  J Clin Sleep Med       Date:  2017-11-15       Impact factor: 4.062

3.  Occurrence and predictors of obstructive sleep apnea in a revascularized coronary artery disease cohort.

Authors:  Helena Glantz; Erik Thunström; Johan Herlitz; Björn Cederin; Salmir Nasic; Jan Ejdebäck; Yüksel Peker
Journal:  Ann Am Thorac Soc       Date:  2013-08

4.  Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline.

Authors:  Vishesh K Kapur; Dennis H Auckley; Susmita Chowdhuri; David C Kuhlmann; Reena Mehra; Kannan Ramar; Christopher G Harrod
Journal:  J Clin Sleep Med       Date:  2017-03-15       Impact factor: 4.062

5.  Behavioral correlates of sleep-disordered breathing in older men.

Authors:  Eric J Kezirian; Stephanie L Harrison; Sonia Ancoli-Israel; Susan Redline; Kristine Ensrud; Andrew N Goldberg; David M Claman; Adam P Spira; Katie L Stone
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

6.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

7.  Continuous positive airway pressure treatment of sleepy patients with milder obstructive sleep apnea: results of the CPAP Apnea Trial North American Program (CATNAP) randomized clinical trial.

Authors:  Terri E Weaver; Cristina Mancini; Greg Maislin; Jacqueline Cater; Bethany Staley; J Richard Landis; Kathleen A Ferguson; Charles F P George; David A Schulman; Harly Greenberg; David M Rapoport; Joyce A Walsleben; Teofilo Lee-Chiong; Indira Gurubhagavatula; Samuel T Kuna
Journal:  Am J Respir Crit Care Med       Date:  2012-07-26       Impact factor: 21.405

8.  Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning.

Authors:  Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack
Journal:  Sleep       Date:  2007-06       Impact factor: 5.849

9.  Gender-related differences in symptoms of patients with suspected breathing disorders in sleep: a clinical population study using the sleep disorders questionnaire.

Authors:  Arschang Valipour; Harald Lothaller; Helmuth Rauscher; Hartmut Zwick; Otto Chris Burghuber; Peretz Lavie
Journal:  Sleep       Date:  2007-03       Impact factor: 5.849

10.  Increased prevalence of anxiety and depression symptoms in patients with coronary artery disease before and after percutaneous coronary intervention treatment.

Authors:  Guoqiang Gu; Yaqing Zhou; Ying Zhang; Wei Cui
Journal:  BMC Psychiatry       Date:  2016-07-22       Impact factor: 3.630

View more
  1 in total

1.  Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research.

Authors:  Omonigho M Bubu; Andreia G Andrade; Ogie Q Umasabor-Bubu; Megan M Hogan; Arlener D Turner; Mony J de Leon; Gbenga Ogedegbe; Indu Ayappa; Girardin Jean-Louis G; Melinda L Jackson; Andrew W Varga; Ricardo S Osorio
Journal:  Sleep Med Rev       Date:  2019-12-12       Impact factor: 11.609

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.